Protocol S: Ranibizumab for PDR

In this interview from ASRS 2016, Dr. Andrew N. Antoszyk discusses the 2 year results from the DRCR.net Protocol S trial assessing the noninferiority of ranibizumab compared with panretinal photocoagulation (PRP) for adults with PDR. Overall, patients who received anti-VEGF injections showed better visual outcomes than those randomized to PRP, and this improvement was particularly significant in those with center-involved DME. In addition, ranibizumab eyes were less likely to lose peripheral field vision or need surgical intervention. Dr. Antoszyk highlights the importance of ongoing long-term follow-up (to year 5) as the ranibizumab group was not able to maintain total VA gains between year 1 and 2.